Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression

J Chemother. 2020 Sep;32(5):268-271. doi: 10.1080/1120009X.2020.1716492. Epub 2020 Jan 25.

Authors

Melania Rivano¹, Luca Cancanelli¹, Andrea Zovi¹, Chiara Addis², Daniele Mengato³, Marco Chiumente³, Andrea Messori³

Affiliations

¹ Department of Pharmaceutical Sciences, Hospital Pharmacy School, University of Milan, Milan, Italy.
² Department of Pharmaceutical Sciences, Hospital Pharmacy School, University of Florence, Florence, Italy.
³ Scientific Direction, Italian Society for Clinical Pharmacy and Therapeutics, Milan, Italy.

PMID: 31984876
DOI: 10.1080/1120009X.2020.1716492

No abstract available

Publication types

Letter
Meta-Analysis

MeSH terms

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Remission Induction
Withholding Treatment / statistics & numerical data*

Substances

Protein Kinase Inhibitors
Protein-Tyrosine Kinases